AI assistant
CONTROL BIONICS LIMITED — Board/Management Information 2025
Nov 30, 2025
64611_rns_2025-11-30_49ba9732-3ab2-459b-9e11-352fecc24d4e.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [177 x 63] intentionally omitted <==
1 December 2025
Control Bionics Appoints Stephen Rix to the Board of Directors
Control Bionics Limited (ASX: CBL), a global leader in assistive communication and neurotechnology, today announced the appointment of Stephen Rix to its Board as a Non-Executive Director and the new Chairman.
Stephen Rix is an experienced chairman, director and chief executive with a distinguished 20-year career growing and guiding companies across financial services, private equity, funds management and high-growth technology. His background includes Chair roles at Travelex Asia Pacific , Bennelong Funds Management Group , and Avenue Bank , Australia’s newest digital bank.
Stephen is currently a Director of Allen & Unwin Pty Ltd , Australia’s leading independent book publisher, and has previously served on the boards of two ASXlisted companies including Colonial First State Private Capital Ltd . He also dedicated 20 years as a trustee of the Australian Cancer Research Foundation , supporting more than $200 million in world-leading cancer research innovation nationally.
Importantly, Stephen has been a long-standing investor in Control Bionics since 2016, providing him with deep familiarity with the company, its mission and its global potential.
Damian Lismore, current Chairman of Control Bionics, said:
“Stephen brings an exceptional track record in governance, growth and capital stewardship across multiple sectors. His long-term belief in Control Bionics as an investor, combined with his extensive experience, will be invaluable as we scale our technology and expand globally. We are delighted to welcome Stephen to the Board.”
Stephen Rix said:
“I have admired Control Bionics for many years — both as an investor and as someone passionate about helping innovative Australian companies grow. The opportunity to contribute more directly at this stage of the company’s journey is compelling. Control Bionics is delivering life-changing technology, and I’m excited to support the team as we accelerate expansion into new markets and new applications.”
This announcement has been authorised for release by the current Chairman, Damian Lismore .
Control Bionics Limited Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462
==> picture [177 x 63] intentionally omitted <==
For further information, please contact:
Investors and Media
Jeremy Steele – CEO and Managing Director [email protected]
Brett Crowley - Company Secretary [email protected]
Investor Relations:
Joe Durak Executive Director & Founder Lynx Advisors [email protected] +61 414 465 582
For further information visit the website: https://www.controlbionics.com/
About Control Bionics:
Control Bionics is a medical device company that more than 20 years’ experience in the development and use of surface Electromyography (EMG) devices.
About NeuroNode
Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.
About NeuroStrip
Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.
Control Bionics has a 22% investment in Neuro Elite Athletics to drive rapid growth of their NeuroBounce program in the US and Australia
Control Bionics operates in North America, Australia, Singapore and Japan.
Control Bionics Limited Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462